Omnicare Pays $4.2M To End FCA Suit Over Amgen Kickbacks

Law360, Washington (February 27, 2014, 7:24 PM EST) -- Omnicare Inc. will pay $4.2 million to settle a whistleblower's False Claims Act suit alleging it solicited and received kickbacks to promote Amgen Inc.'s Aranesp anemia drug among Medicaid patients, the U.S. Department of Justice said Thursday.

The deal resolves allegations that Omnicare sought and received performance-based rebates from Amgen in exchange for implementing “therapeutic interchange” programs designed to switch elderly nursing home patients from a competitor drug to Aranesp, the DOJ said.

“Kickbacks are designed to influence decisions by health care providers, such as which...
To view the full article, register now.